TriangleNCT03846427 · OUTCOME
Duration of Response (DOR) by Investigator Assessment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- Up to approximately 3 years and 2.5 months
What was measured
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.
Analysis population: Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug; DOR was summarized for responders only, defined as participants with a best overall response of partial response or above.
Groups in this outcome
Zanubrutinib
Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
| Group | Source count |
|---|---|
| Zanubrutinib | 50 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zanubrutinib | NA | Not reported | 22.1 | NA | Not estimable due to insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- comment
- Not estimable due to insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 22.1
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 50
- units
- Participants
- description
- DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using Lugano Classification.
- dispersion Type
- Full Range
- groups
- description
- Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
- id
- OG000
- title
- Zanubrutinib
- param Type
- MEDIAN
- population Description
- Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug; DOR was summarized for responders only, defined as participants with a best overall response of partial response or above.
- reporting Status
- POSTED
- time Frame
- Up to approximately 3 years and 2.5 months
- title
- Duration of Response (DOR) by Investigator Assessment
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice